---
title: "Vertex Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299486700.md"
description: "Vertex Pharmaceuticals (VRTX) shares fell 1.55% to $508.34 on Friday, underperforming the broader market as the S&P 500 rose slightly while the Dow dipped. The stock closed 9.27% below its 52-week high of $560.25 reached in September. Compared to competitors like AbbVie and Krystal Biotech, Vertex's performance was mixed amid a generally volatile trading session."
datetime: "2026-09-18T20:36:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299486700.md)
  - [en](https://longbridge.com/en/news/299486700.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299486700.md)
generator: "portal-rs"
---

# Vertex Pharmaceuticals Inc. Stock Underperforms Friday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Vertex Pharmaceuticals Inc. (VRTX) shed 1.55% to $508.34 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.17% to 7,650.50 and the Dow Jones Industrial Average falling 0.18% to 51,682.64.

Vertex Pharmaceuticals Inc. closed 9.27% below its 52-week high of $560.25, which the company reached on September 3rd.

The stock demonstrated a mixed performance when compared to some of its competitors Friday, as AbbVie Inc. (ABBV) fell 0.02% to $263.96, Krystal Biotech Inc. (KRYS) fell 0.61% to $336.67, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 5.32% to $16.03.

Data source: Dow Jones Market Data, FactSet. Data compiled September 18, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

09-18-26 1636ET

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)
- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Vertex spends its CF growth on new launches: rapid earnings reaction](https://longbridge.com/en/news/304020286.md)
- [Is Vertex Pharmaceuticals (VRTX) A Bargain After Its Phase 3 Kidney Trial Win?](https://longbridge.com/en/news/302977895.md)
- [Casgevy gains UK label expansion for younger patient population](https://longbridge.com/en/news/303769098.md)
- [Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III](https://longbridge.com/en/news/302938807.md)
- [Vertex Pharmaceuticals Publishes Presentation on Kidney Disease Research](https://longbridge.com/en/news/302935011.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**